<DOC>
	<DOCNO>NCT00944229</DOCNO>
	<brief_summary>A diet rich Omega-3 ( fish oil ) reduce plasma triglyceride risk ischemic heart disease . Recently , large trial evaluate treatment Omega 3 heart failure patient suggest omega 3 may lower risk death CHF . The mechanism potential benefit well understood . Methods : Forty patient enrol study . Twenty patient receive Omega 3 ( lovaza 4 gm day ) 20 patient receive placebo . All subject assessment exercise capacity blood vessel function 8 week treatment period . About 4 table spoon blood drawn throughout study . Expected result : The investigator believe omega 3 may improve ability exercise improve blood vessel function .</brief_summary>
	<brief_title>The Effect Omega-3 Polyunsaturated Fatty Acids Congestive Heart Failure</brief_title>
	<detailed_description>A diet rich Omega-3 polyunsaturated fatty acid Omega 3 reduces plasma triglyceride risk ischemic heart disease1 , may exert direct antiarrhythmic effect myocardium 2-9 . A post-hoc analysis GISSI-Prevenzione trial demonstrate reduction all-cause sudden mortality subgroup nearly 2000 post-infarction patient leave ventricular dysfunction 10 . This provocative finding prospectively study large-scale , randomize , double-blind study design investigate effect Omega 3 mortality morbidity patient symptomatic heart failure ( GISSI Heart Failure project ) . The result GISSI-HF trial demonstrate 1 g per day Omega 3 associate 9 % reduction mortality cardiovascular admission patient predominantly systolic heart failure , add optimal medical therapy11 . The mechanism ( ) underlie beneficial effect remain elucidated critical fully exhaust therapeutic benefit Omega 3 CHF . We recently demonstrate lipid oxidation acute exercise alter patient CHF 12 degree alteration carry prognostic significance . It conceivable Omega 3 modulates lipid oxidation exercise thereby favorably effect outcome . Accordingly propose study effect Omega 3 lipid oxidation exercise CHF . We examine VO2 endothelial function present principal surrogate marker survival CHF 13 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>All subject CHF due systolic dysfunction follow outpatient facility Columbia University Medical Center screen subject ask participate follow criterion meet : Older 18 year . Symptomatic heart failure ( New York Heart Association functional class IIIII ) . Ischemic nonischemic cardiomyopathy . Left ventricular ejection fraction ( EF ) 40 % low . Peak oxygen uptake ( VO2 , peak ) 10 17 mL O2/min/kg . Be appropriate , stable medical treatment heart failure , include ( unless show intolerant ) diuretic , angiotensinconverting enzyme inhibitor and/or angiotensinreceptor blocker betablocker , pacemaker ICD CRT . Unable perform treadmill exercise Pregnancy Recent myocardial infarction ( within 3 month ) . Clinically significant angina . Hospitalization heart failure require intravenous treatment within 30 day . Allergy fish</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>omega 3</keyword>
	<keyword>lovaza</keyword>
	<keyword>VO2 max</keyword>
</DOC>